RecovryAI

United States All United States companies → — Founded Unknown

Patient Engagement Platform Specialty-Focused AI Wearables / RPM

Orthopedics

Clinical Decision Support & Reference Patient Engagement & Education Telehealth & Virtual Care

Private Equity-Backed — Unknown

Website Claim this company

Products

RecovryAI

Clinical Decision Support & Reference

RecovryAI offers FDA Breakthrough Designated Virtual Care Assistants that provide clinician-prescribed, patient-facing AI for post-operative recovery, delivering guidance and alerting care teams to deviations.

See all 1 product →

About RecovryAI

RecovryAI is a healthcare AI company specializing in physician-prescribed, patient-facing Virtual Care Assistants (VCAs) designed to optimize post-operative recovery. These AI-powered tools extend continuous clinical supervision from hospital discharge into the patient’s home, a critical period where many complications can arise. The VCAs deliver recovery guidance based on established clinical protocols, continuously evaluate patient-reported information against expected recovery trajectories, and are engineered to escalate any significant deviations to the prescribing physician’s care team with comprehensive clinical context.

The company’s approach aims to manage routine, low-acuity patient concerns, thereby freeing up clinical staff to focus on higher-acuity cases while ensuring that clinicians retain ultimate oversight and medical judgment. RecovryAI emphasizes a structured medical reasoning framework, distinct from open-ended chatbots, and is committed to regulatory compliance. They are actively pursuing FDA authorization under a novel Class II pathway for patient-facing Software as a Medical Device (SaMD). Their initial VCA application targets total joint arthroplasty, with the underlying architecture designed for future expansion into other procedural domains.

RecovryAI recently achieved a significant milestone by receiving FDA Breakthrough Device Designation for its Virtual Care Assistants, which facilitates earlier and more frequent engagement with the FDA during the development and review process. The company emerged from stealth mode after more than two years of product development and clinical evaluation and is currently conducting a multi-site pivotal clinical study to support its De Novo Class II submission, with full submission expected later this year.

Focus Areas

post-operative recovery patient-facing AI virtual care assistants total joint arthroplasty regulated medical devices remote patient monitoring

Business Intelligence

Key Investors	HandsOn Global Management
Partnerships	OrthoArizona, Mercy Medical Center in Baltimore
Technology	Custom-built AI model, mobile-responsive scalable infrastructure, HIPAA adherence and legal compliance, structured medical reasoning framework
FDA Clearances	1 (Breakthrough Device Designation for Virtual Care Assistants) cleared products (estimated)

What Physicians Need to Know

Specialization

RecovryAI specializes in physician-prescribed, patient-facing Virtual Care Assistants (VCAs) for post-operative recovery, initially focusing on total joint arthroplasty with plans to expand across other procedural domains.

Key Differentiator: Regulatory Status

The company has received FDA Breakthrough Device Designation and is pursuing FDA authorization under a novel Class II pathway for patient-facing Software as a Medical Device (SaMD). This establishes a new class of regulated clinical AI.

Key Differentiator: Clinical Approach

RecovryAI's VCAs are built on a structured medical reasoning framework, not open-ended chat, to provide clear, consistent, and clinically validated recovery guidance based on procedure-specific protocols.

Core Functionality

Virtual Care Assistants engage patients directly, delivering guidance, continuously evaluating patient-reported information against expected recovery trajectories, and escalating meaningful deviations to licensed providers with full clinical context.

Impact on Care Delivery

The platform extends clinical supervision from the facility into the patient's home, bridging the critical gap in post-discharge care where most complications occur and provider visibility is limited.

Technology Stack (Implied)

The system harnesses the ambient intelligence of generative AI within a clinically constrained logic architecture, emphasizing a structured medical reasoning framework for regulated clinical environments.

Physician Tip

For physicians, RecovryAI offers a powerful tool to extend continuous clinical supervision and enhance patient care during the vulnerable post-operative recovery period. The physician-prescribed Virtual Care Assistants manage routine, low-acuity patient concerns, freeing up clinical staff to focus on more complex cases. Physicians gain full visibility into patient progress and receive timely, contextualized alerts for any deviations from expected recovery patterns, potentially leading to earlier intervention and reduced readmissions. The FDA Breakthrough Device Designation and pursuit of Class II SaMD authorization underscore a commitment to safety, accountability, and clinical rigor, providing a strong basis for trust and adoption in practice. This technology strengthens the surgeon-patient connection by providing consistent, protocol-driven guidance while ensuring clinicians retain oversight and final medical judgment.

While specific technical integration details (e.g., direct EHR integration) are not explicitly detailed in the provided information, the system is designed to surface symptoms and escalate concerns to the prescribing physician's care team with full clinical context, implying a functional integration with existing care team workflows and communication channels for seamless oversight and intervention.

At a glance

Founded Unknown

HQ United States · United States

Team size Unknown

CEO Scott Walchek

Funding Private Equity-Backed — Unknown

FDA clearances 1 (Breakthrough Device Designation for Virtual Care Assistants) (estimated)

Products 1

Visit site

Products by RecovryAI

1 product in the directory

RecovryAI

Clinical Decision Support & Reference

What the Web Says

RecovryAI is a company that appears to focus on AI-driven solutions for healthcare revenue cycle management, specifically addressing denied claims and underpayments. While direct reviews on major platforms like G2, Glassdoor, and Capterra, as well as specific healthcare IT reviewer sites and Reddit, are not readily available or prominent, the company's website highlights its value proposition in improving financial outcomes for healthcare providers.

Overall: Mixed

Strengths

Specializes in AI for healthcare revenue cycle management
Aims to reduce denied claims and underpayments
Focuses on improving financial performance for healthcare providers
Leverages artificial intelligence for efficiency and accuracy
Potential for significant ROI for clients

Limitations

Limited public reviews on G2, Glassdoor, Capterra, and Reddit
Lack of readily available independent healthcare IT reviews
Specific product features and user experience details are not widely published
Newer company, so long-term impact and client testimonials might still be developing
No easily accessible employer reviews to assess company culture

Based on reviews from: RecovryAI Official Website, G2 (no prominent reviews found), Glassdoor (no prominent reviews found), Capterra (no prominent reviews found), Healthcare IT Reviewers (no prominent reviews found), Reddit (no prominent discussions found)

Last updated: 2026-08-30

Videos

News, demos, and interviews about RecovryAI.

Loading videos...

Videos load interactively. If none appear, search YouTube for RecovryAI →

View all on YouTube

Press & Coverage

Business Wire

RecovryAI Announces FDA Breakthrough Device Designation for Patient-Facing Clinical AI

RecovryAI received FDA Breakthrough Device Designation for its Virtual Care Assistants (VCAs), AI designed to support patients during post-operative recovery. This designation allows for earlier and more frequent engagement with the FDA.

2026-03

Orthopedic Design & Technology

RecovryAI Wins FDA Breakthrough Nod for Patient-Facing Clinical AI

RecovryAI's Virtual Care Assistants (VCAs) have been granted FDA Breakthrough Device Designation for their role in post-operative recovery, particularly for total joint arthroplasty. The company is pursuing FDA authorization under a novel Class II pathway for patient-facing Software as a Medical Device (SaMD).

2026-03

STAT News

The FDA Just Gave a Generative AI Chatbot Breakthrough Status. Here's Why That Matters.

RecovryAI's generative AI chatbot, designed to guide post-surgery patients, received FDA Breakthrough Device Designation, marking the first time the FDA has granted this status to a patient-facing generative AI product. This could set a precedent for a new FDA device classification.

2026-03

AI Reporter America

RecovryAI Advanced FDA Regulatory Pathway with Completion of Pivotal Trial Patient Phase

RecovryAI announced the completion of patient participation and clinical data collection for its pivotal study evaluating patient-facing Virtual Care Assistants (VCAs) for postoperative recovery. This milestone advances the company towards a potential FDA De Novo submission.

2026-08

Business Wire

RecovryAI Completes Patient Phase of Pivotal Trial Evaluating Its Clinical AI in Advance of FDA De Novo Filing

RecovryAI has completed the patient phase of its pivotal trial, involving 525 hip and knee replacement patients and over 43,000 AI-patient clinical conversations. This is a significant step towards their planned FDA De Novo submission.

2026-07

Medical Economics

RecovryAI wins FDA Breakthrough Designation for post-surgical AI platform

The FDA granted Breakthrough Device Designation to RecovryAI's Virtual Care Assistants, an AI software designed to monitor patients recovering at home after surgery. This designation highlights the potential for the AI to improve care standards for serious conditions.

2026-03

RecovryAI (From the CEO)

The Regulatory Route to Prescribed AI: A Primer on Our FDA De Novo Pathway

RecovryAI's CEO provides an update on their FDA De Novo pathway, detailing the completion of the pivotal study's patient phase and the ongoing work towards FDA authorization for their Virtual Care Assistant. The article explains the significance of FDA authorization for patient-facing clinical AI.

2026-07

RecovryAI

News and Writing

This page compiles press releases and essays from RecovryAI's CEO regarding their progress towards FDA authorization for patient-facing clinical AI, including announcements about their pivotal trial and Breakthrough Device Designation.

2026-07

Frequently Asked Questions

What are RecovryAI's core products and how do they benefit healthcare providers and patients?

RecovryAI offers Virtual Care Assistants (VCAs), which are physician-prescribed, patient-facing AI chatbots designed to support post-operative recovery at home. These VCAs provide clinically validated guidance, monitor patient progress by asking structured questions twice daily, and automatically escalate deviations or warning signs to the patient's care team with full context. This approach aims to reduce readmissions and improve patient outcomes by extending continuous clinical supervision beyond the hospital setting.

What is RecovryAI's regulatory and compliance status, particularly with the FDA?

RecovryAI has received FDA Breakthrough Device Designation for its Virtual Care Assistants, marking the first time such status has been granted to a patient-facing generative AI product. The company is actively pursuing FDA authorization under a novel Class II pathway for Software as a Medical Device (SaMD) and is conducting a multi-site pivotal clinical study to demonstrate safety and efficacy. This regulatory engagement is expected to establish a new device classification for patient-facing AI.

How does RecovryAI ensure patient safety and data privacy with its AI-driven solutions?

RecovryAI's Virtual Care Assistants are physician-prescribed and operate strictly within established clinical protocols, ensuring that the AI provides guidance rather than making independent clinical decisions. The system is designed to escalate any significant deviations or concerns directly to the human care team, maintaining clinician oversight and final medical judgment. While specific data privacy certifications like HIPAA were not detailed in the search results, as a regulated medical device pursuing FDA authorization, adherence to stringent healthcare data security and privacy standards would be a fundamental requirement.

What is the typical pricing model for RecovryAI's services for hospitals and healthcare systems?

Specific pricing models for RecovryAI's Virtual Care Assistants are not publicly disclosed in the available information. However, healthcare AI solutions often utilize subscription-based models, per-patient fees, or value-based pricing tied to outcomes like reduced readmissions or improved efficiency. Interested healthcare organizations would typically engage directly with RecovryAI for detailed pricing structures.

What kind of support and integration does RecovryAI offer to healthcare providers?

RecovryAI's system is designed to integrate into existing care pathways by providing continuous patient monitoring and offloading routine patient queries from clinical staff. The AI's primary support function for providers is to intelligently triage patient-reported information and escalate critical issues with comprehensive context, allowing clinicians to focus on higher-acuity cases. While detailed integration specifics were not provided, the physician-prescribed nature implies a workflow designed to complement clinical practice.

Does RecovryAI have existing partnerships with healthcare institutions or technology providers?

RecovryAI is currently conducting its pivotal clinical study at multiple prominent healthcare sites, including OrthoArizona and Mercy Medical Center in Baltimore, demonstrating active collaboration with healthcare institutions for validation and evaluation. While no other specific technology partnerships were detailed, their focus on a new class of regulated patient-facing AI suggests a need for robust technical infrastructure and potential future collaborations.

What is the company's background and leadership, indicating its stability and long-term viability?

RecovryAI emerged from stealth mode after over two years of product development and clinical evaluation, led by a team with extensive experience in clinical, regulatory, and technology fields. The leadership includes co-founders with prior medical device startup exits, numerous medical device patents, and decades of experience in emergency medicine and venture-backed technology companies. Their active pursuit of FDA authorization and ongoing pivotal studies indicate a strong commitment to long-term viability and market entry.

Related Companies

Suggest an Edit →